Table 5.

Treatment of Manifestations in Individuals with LCHAD/TFP Deficiency

Manifestation/
Concern
TreatmentConsiderations/Other
Defect of
long-chain
fatty acid
oxidation
Avoidance of fasting
  • Birth-age 3 mos: frequent feeds (every 2-3 hrs)
  • Age 4-12 mos: feeding interval can be ↑ to every 4 hrs if tolerated by 6 mos. From age 6 to 12 mos, daytime feeding interval every 4 hrs; overnight fasting can be gradually ↑ to 6-8 hrs by 12 mos.
  • Age 1-3 yrs: daytime feeding interval 4 hrs; overnight fasting up to 10 hrs may be attempted
  • Age 3+ yrs: overnight fasting up to 12 hrs may be attempted
  • ↓ feeding interval by half during periods of illness.
  • After age 1 yr, if preprandial hypoglycemia remains an issue, consider overnight feedings or 1 gm/kg of uncooked cornstarch at bedtime to ensure sufficient glucose supply overnight.
MCT supplementation
  • Low-fat diet recommended
  • Goal: provide 30% of energy needs from fat incl 7%-15% from long-chain fat & 15%-25% from MCT
MCT can bypass carnitine shuttle & enter mitochondria directly. As medium-chain fatty acid oxidation is intact, it provides important source of calories & is cornerstone of mgmt in long-chain FAOD.
Triheptanoin (C7)
  • Approved by FDA in 2020 for treatment of long-chain FAODs; can be used as an alternative to MCT to provide up to 35% of daily calorie intake.
  • Triheptanoin treatment can ↓ frequency of hospitalizations & rhabdomyolysis 1 & improve cardiomyopathy, hepatomegaly, & hypoglycemia. 2
  • Adverse effects are mainly gastrointestinal & transient (e.g., abdominal pain, diarrhea).
Triheptanoin is an odd-chain MCT consisting of 3 7-carbon fatty acids metabolized to acetyl CoA & propionyl CoA. Propionyl CoA provides an anaplerotic effect by replenishing mitochondrial tricarboxylic acid cycle intermediates. Thus, compared to even-chain MCT, triheptanoin provides addl benefits through anaplerosis. 3
Secondary
carnitine
deficiency
L-carnitine: 25-50 mg/kg daily in 3 divided dosesCarnitine supplementation is NOT recommended unless there is carnitine deficiency because of concern for cardiotoxicity of long-chain hydroxyacylcarnitine derivatives.
Poor weight
gain / FTT
  • Feeding therapy
  • Gastrostomy tube placement may be required for persistent feeding issues.
Low threshold for clinical feeding eval &/or radiographic swallowing study if clinical signs or symptoms of dysphagia
DD/ID Interventions per developmental pediatrician / neurodevelopment specialistPT, OT, & speech therapy, as indicated
Cardiac
dysfunction
Interventions per cardiologistEarly diagnosis & strict dietary therapy can prevent & even reverse cardiomyopathy. 4
Peripheral
neuropathy
Interventions per neurologistEarly diagnosis & strict dietary therapy may delay onset or slow progression but may not completely prevent this complication. 5
Retinopathy Interventions per ophthalmologistEarly diagnosis & strict dietary therapy may delay onset or slow progression but may not completely prevent this complication. 6

CoA = coenzyme A; DD/ID = developmental delay /intellectual disability; FAOD = fatty acid oxidation disorders; FTT = failure to thrive; LCHAD = long-chain hydroxyacyl-CoA dehydrogenase; MCT = medium-chain triglyceride; OT = occupational therapy; PT = physical therapy; TFP = trifunctional protein

1.
2.
3.
4.
5.
6.

From: Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency / Trifunctional Protein Deficiency

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.